All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
During the 2021 ASCO Annual Meeting, the AML Hub spoke with Hui Zhang, Guangzhou Women and Children's Medical Center, Guangzhou, CN. We asked, How efficacious is CAR-T in childhood AML?
How efficacious is CAR-T in childhood AML?
Zhang begins by outlining novel approaches to improve prognosis in relapsed/refractory patients, highlighting the increasing role of CAR T-cell therapy in pediatric AML. He then describes the encouraging results and response rates of his project, presented at ASCO. Finally, Zhang discusses which patients might benefit from CAR T-cell therapy, such as those who are unresponsive to tyrosine kinase inhibitors (TKIs).
How can we improve efficacy of CAR T-cell therapy in AML?
During the 3rd European CAR T-cell Meeting, the AML Hub spoke to Naval Daver, MD Anderson Cancer Center, Houston, US. We asked, How can we improve efficacy of CAR T-cell therapy in AML?
Implementation of CAR T-cell therapy in the real world - A round table discussion
The AML Hub is pleased to report a summary of real-world experiences of chimeric antigen receptor (CAR) T-cell implementation as discussed at the 2nd European CAR...
Subscribe to get the best content related to AML delivered to your inbox